公开(公告)号：US20190225583A1

公开(公告)日：2019-07-25

申请号：US16289878

申请日：2019-04-10

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Saleem Ahmad ,  Douglas G. Batt ,  Qingjie Liu ,  John E. Macor ,  Joseph A. Tino ,  Scott Hunter Watterson ,  Satheesh Kesavan Nair ,  Tarun Kumar Maishal

IPC: C07D209/88 ,  C07D495/04 ,  C07D403/12 ,  C07D471/10 ,  C07D487/04 ,  A61K31/4523 ,  C07D403/06 ,  C07D471/04 ,  C07D403/04 ,  C07D401/04 ,  C07D401/06

Abstract: Disclosed are compounds of Formula (I): or a salt thereof, wherein Q, R1a, R1b, R2a, R2b, R3, R4, R5a, R5b, R6a, R6c, R7a, R7b, R7c, and R7d are defined herein. Also disclosed are methods of using such compounds as inhibitors of Bruton's tyrosine kinase (Btk), and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

公开(公告)号：US20190023719A1

公开(公告)日：2019-01-24

申请号：US16140750

申请日：2018-09-25

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Douglas G. Batt ,  Myra Beaudoin Bertrand ,  George V. De Lucca ,  Michael A. Galella ,  Soo Sung Ko ,  Charles M. Langevine ,  Qingjie Liu ,  Qing Shi ,  Anurag S. Srivastava ,  Joseph A. Tino ,  Scott Hunter Watterson

IPC: C07D513/04 ,  C07D209/88 ,  C07D471/04 ,  C07D403/10 ,  C07D239/70

CPC classification number: C07D513/04 ,  C07B2200/07 ,  C07B2200/13 ,  C07D209/88 ,  C07D239/70 ,  C07D403/10 ,  C07D471/04

Abstract: Disclosed are compounds of Formula (I) wherein: the two dotted lines represent either two single or two double bonds; Q is: R1 is F, Cl, —CN, or —CH3; R2 is Cl or —CH3; R3 is —C(CH3)2OH or —CH2CH2OH; Ra is H or —CH3; each Rb is independently F, Cl, —CH3, and/or —OCH3; and n is zero, 1, or 2. Also disclosed are methods of using such compounds as inhibitors of Bruton's tyrosine kinase (Btk), and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

公开(公告)号：US09850258B2

公开(公告)日：2017-12-26

申请号：US15625417

申请日：2017-06-16

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Scott Hunter Watterson

IPC: C07D209/88 ,  C07D513/04 ,  C07D471/04 ,  C07D403/10 ,  C07D239/70

CPC classification number: C07D513/04 ,  C07B2200/07 ,  C07B2200/13 ,  C07D209/88 ,  C07D239/70 ,  C07D403/10 ,  C07D471/04

Abstract: Disclosed are compounds of Formula (I) wherein: the two dotted lines represent either two single or two double bonds; Q is: R1 is F, Cl, —CN, or —CH3; R2 is Cl or —CH3; R3 is —C(CH3)2OH or —CH2CH2OH; Ra is H or —CH3; each Rb is independently F, Cl, —CH3, and/or —OCH3; and n is zero, 1, or 2. Also disclosed are methods of using such compounds as inhibitors of Bruton's tyrosine kinase (Btk), and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

公开(公告)号：US20160115126A1

公开(公告)日：2016-04-28

申请号：US14921347

申请日：2015-10-23

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Qingjie Liu ,  Scott Hunter Watterson ,  Douglas G. Batt ,  Saleem Ahmad ,  Myra Beaudoin Bertrand ,  Hua Gong ,  Weiwei Guo ,  John E. Macor ,  Khehyong Ngu ,  Andrew J. Tebben ,  Joseph A. Tino

IPC: C07D209/08 ,  C07D403/10 ,  C07D403/12 ,  C07D403/04 ,  C07D487/10 ,  C07D487/04 ,  C07D413/04 ,  C07D471/04 ,  C07D401/06 ,  C07D417/04 ,  C07D401/04 ,  C07D401/12

CPC classification number: C07D401/10 ,  C07D209/08 ,  C07D209/18 ,  C07D401/04 ,  C07D401/06 ,  C07D401/12 ,  C07D403/04 ,  C07D403/10 ,  C07D403/12 ,  C07D413/04 ,  C07D417/04 ,  C07D471/04 ,  C07D487/04 ,  C07D487/10

Abstract: Disclosed are compounds of Formula (I): or a salt thereof, wherein: X is CR4 or N; R1, R2, R3, R4, and A are defined herein. Also disclosed are methods of using such compounds as inhibitors of Bruton's tyrosine kinase (Btk), and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

Abstract translation: 公开了式（I）的化合物或其盐，其中：X是CR 4或N; R1，R2，R3，R4和A在本文中定义。 还公开了使用这种化合物作为Bruton酪氨酸激酶（Btk）的抑制剂的方法和包含这些化合物的药物组合物。 这些化合物可用于治疗，预防或减缓各种治疗领域（例如自身免疫性疾病和血管疾病）中的疾病或病症的进展。

公开(公告)号：US11623921B2

公开(公告)日：2023-04-11

申请号：US17110643

申请日：2020-12-03

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Qingjie Liu ,  Scott Hunter Watterson ,  John E. Macor ,  Khehyong Ngu ,  Saleem Ahmad

IPC: C07D417/04 ,  C07D401/10 ,  C07D403/12 ,  C07D401/04 ,  C07D401/06 ,  C07D401/12 ,  C07D403/04 ,  C07D403/10 ,  C07D413/04 ,  C07D471/04 ,  C07D487/04 ,  C07D487/10 ,  C07D209/18 ,  A61P29/00 ,  A61P37/00 ,  C07D209/08

Abstract: Disclosed are compounds of Formula (I): or a salt thereof, wherein: X is CR4 or N; R1, R2, R3, R4, and A are defined herein. Also disclosed are methods of using such compounds as inhibitors of Bruton's tyrosine kinase (Btk), and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

公开(公告)号：US10604504B2

公开(公告)日：2020-03-31

申请号：US16396879

申请日：2019-04-29

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Qingjie Liu ,  Scott Hunter Watterson ,  John E. Macor ,  Khehyong Ngu ,  Saleem Ahmad

IPC: A61K31/436 ,  A61P35/04 ,  C07D401/10 ,  C07D403/12 ,  C07D401/04 ,  C07D401/06 ,  C07D401/12 ,  C07D403/04 ,  C07D403/10 ,  C07D413/04 ,  C07D417/04 ,  C07D471/04 ,  C07D487/04 ,  C07D487/10 ,  C07D209/18 ,  A61P29/00 ,  A61P37/00 ,  C07D209/08

Abstract: Disclosed are compounds of Formula (I): or a salt thereof, wherein: X is CR4 or N; R1, R2, R3, R4, and A are defined herein. Also disclosed are methods of using such compounds as inhibitors of Bruton's tyrosine kinase (Btk), and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

公开(公告)号：US20190389859A1

公开(公告)日：2019-12-26

申请号：US16484604

申请日：2018-02-12

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Junqing Guo ,  Amy C. Hart ,  John E. Macor ,  Michael E. Mertzman ,  William J. Pitts ,  Steven H. Spergel ,  Scott Hunter Watterson ,  Murugaiah Andappan Murugaiah Subbaiah ,  Jie Chen ,  Carolyn Diane Dzierba ,  Guanglin Luo ,  Jianliang Shi ,  Sing-Yuen Sit

IPC: C07D471/04

Abstract: Compounds having formula (I) (IX), and enantiomers, and diastereomers, stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein: (I), (II), (III), (IV), (V), (VI), (VII), (VIII), (IX).

公开(公告)号：US10106559B2

公开(公告)日：2018-10-23

申请号：US15809437

申请日：2017-11-10

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Douglas G. Batt ,  Myra Beaudoin Bertrand ,  George V. Delucca ,  Michael A. Galella ,  Soo Sung Ko ,  Charles M. Langevine ,  Qingjie Liu ,  Qing Shi ,  Anurag S. Srivastava ,  Joseph A. Tino ,  Scott Hunter Watterson

IPC: C07D513/04 ,  C07D471/04 ,  C07D403/10 ,  C07D239/70 ,  C07D209/88

Abstract: Disclosed are compounds of Formula (I) wherein: the two dotted lines represent either two single or two double bonds; Q is: R1 is F, Cl, —CN, or —CH3; R2 is Cl or —CH3; R3 is —C(CH3)2OH or —CH2CH2OH; Ra is H or —CH3; each Rb is independently F, Cl, —CH3, and/or —OCH3; and n is zero, 1, or 2. Also disclosed are methods of using such compounds as inhibitors of Bruton's tyrosine kinase (Btk), and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

公开(公告)号：US09920031B2

公开(公告)日：2018-03-20

申请号：US15608340

申请日：2017-05-30

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Qingjie Liu ,  Scott Hunter Watterson ,  Saleem Ahmad

IPC: A01N43/00 ,  A61K31/397 ,  C07D401/10 ,  C07D209/08 ,  C07D209/18 ,  C07D401/04 ,  C07D401/06 ,  C07D401/12 ,  C07D471/04 ,  C07D487/10 ,  C07D487/04

CPC classification number: C07D401/10 ,  C07D209/08 ,  C07D209/18 ,  C07D401/04 ,  C07D401/06 ,  C07D401/12 ,  C07D403/04 ,  C07D403/10 ,  C07D403/12 ,  C07D413/04 ,  C07D417/04 ,  C07D471/04 ,  C07D487/04 ,  C07D487/10

Abstract: Disclosed are compounds of Formula (I): or a salt thereof, wherein: X is CR4 or N; R1, R2, R3, R4, and A are defined herein. Also disclosed are methods of using such compounds as inhibitors of Bruton's tyrosine kinase (Btk), and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

公开(公告)号：US12157733B2

公开(公告)日：2024-12-03

申请号：US17116016

申请日：2020-12-09

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Junqing Guo ,  Amy C. Hart ,  John E. Macor ,  Michael E. Mertzman ,  William J. Pitts ,  Steven H. Spergel ,  Scott Hunter Watterson ,  Murugaiah Andappan Murugaiah Subbaiah ,  Jie Chen ,  Carolyn Diane Dzierba ,  Guanglin Luo ,  Jianliang Shi ,  Sing-Yuen Sit

IPC: C07D471/04

Abstract: Compounds having formula (I)-(IX), and enantiomers, and diastereomers, stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein.